BETAXOLOL HYDROCHLORIDE (betaxolol hydrochloride) by Novartis is clinical pharmacology: betaxolol is a ß 1 -selective (cardioselective) adrenergic receptor blocking agent that has weak membrane-stabilizing activity and no intrinsic sympathomimetic (partial agonist) activity. Approved for the management of hypertension, hypertension. First approved in 2008.
Drug data last refreshed 19h ago
CLINICAL PHARMACOLOGY: Betaxolol is a ß 1 -selective (cardioselective) adrenergic receptor blocking agent that has weak membrane-stabilizing activity and no intrinsic sympathomimetic (partial agonist) activity. The preferential effect on ß 1 receptors is not absolute, however, and some inhibitory…
Worked on BETAXOLOL HYDROCHLORIDE at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Levobetaxolol Hydrochloride Eye Drops for Treatment of Primary Open-angle Glaucoma or Ocular Hypertension